Publication: Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: A single center experience from Thailand
Issued Date
2010-03-08
Resource Type
ISSN
17568722
Other identifier(s)
2-s2.0-77649112614
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Hematology and Oncology. Vol.3, (2010)
Suggested Citation
Pimjai Niparuck, Ladda Sorakhunpipitkul, Vichai Atichartakarn, Suporn Chuncharunee, Artit Ungkanont, Pantep Aungchaisuksiri, Teeraya Puavilai, Saengsuree Jootar Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: A single center experience from Thailand. Journal of Hematology and Oncology. Vol.3, (2010). doi:10.1186/1756-8722-3-1 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/28760
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: A single center experience from Thailand
Other Contributor(s)
Abstract
Background. Thalidomide based regimen is an effective and well tolerated therapy in multiple myeloma (MM) patients, however, there were a small number of studies written about the results of thalidomide therapy in non-transplant MM patients. We therefore conducted a retrospective study of 42 consecutive patients with newly diagnosed and relapsed/refractory MM treated with thalidomide- based induction regimens followed by thalidomide maintenance therapy. Results. Induction regimens with thalidomide and dexamethasone, and the oral combination of melphalan, prednisolone and thalidomide were administrated in 22 and 16 patients, respectively. The remaining 4 patients received other thalidomide- containing regimens. Twenty-nine patients received thalidomide as a salvage regimen. Twenty-three out of 26 patients achieving complete remission (CR) and very good partial remission (VGPR) received thalidomide maintenance. Of the 41 evaluable patients, median time of treatment was 21 months (3- 45 months), ORR was 92.7% with a 63.4% CR/VGPR. With a median follow up of 23 months, 3-year- PFS and 3-year-OS were 58.6 and 72.6%, respectively. Median time to progression was 42 months. While 3-year-PFS and 3-year-OS in non-transplant patients receiving thalidomide maintenance therapy were 67 and 80%, respectively. Conclusions. Prolonged thalidomide therapy enhanced survival rate and less frequently developed serious toxicity in non-transplant multiple myeloma patients. © 2010 Niparuck et al; licensee BioMed Central Ltd.